

## Cumulative Index 2004

### Volume 20

---

February	ALZHEIMER'S DISEASE AND DEMENTIA, pages 1–157
May	ANTI-AGING, pages 157–387
August	GERIATRIC INCONTINENCE, pages 399–592
November	PALLIATIVE CARE I: PROVIDING CARE, pages 593–824

---

*Note:* Page numbers of article titles are in **boldface** type.

### A

- a $\beta$  clearance, Alzheimer's disease and, 146
- Access to Medical Treatment Act, 377–378
- Acculturation, dementias and, 100–101
- Acetaminophen, in pain management, 624
- Acetylcholinesterase inhibitors, efficacy of, in  
mild to moderate Alzheimer's disease,  
61–62  
in Alzheimer's disease, 59–61  
in dementia with Lewy bodies, 64–65  
in moderate to severe Alzheimer's  
disease, 62–63  
in Parkinson's disease, 65  
in vascular dementia, 63–64  
pharmacokinetics of, 60–61
- Activities of daily living, basic and  
instrumental activities of, 7
- Acupressure, 166
- Acupuncture, 166
- Advance directives, home care and, 802–803
- Advanced practice nurses, areas of practice  
by, 492  
assessment of urinary incontinence by,  
489–493  
collaboration with other health  
professionals, 493  
history taking by, in urinary  
incontinence, 490  
identification of type of urinary  
incontinence by, 493
- physical examination by, 490  
in urinary incontinence, 490  
urology or gynecology referrals by, 492
- Advanced practice nursing concepts, caring for  
incontinent elder and, **487–495**
- African American Acculturation Scale, 100
- Age, as risk factor for cancer, 294–297
- Aging, and cognitive function, 16  
and incontinence, 410–411  
biologic changes of, mainimzing of,  
202–205  
definition of, 329  
exercise and, **201–221**  
vitamins and, 80–82
- Agitation, and difficult behavior, in dementia,  
management of, **69–82**
- Alcohol abuse, as cause of cognitive  
impairment, 32
- Alcohol consumption, cancers associated  
with, 301
- Alternative medicine, definition of, 159–160  
in changing world, 159–160
- Alzheimer, Alois, 15
- Alzheimer's Association, 135–136
- Alzheimer's disease, 1, 12  
a $\beta$  clearance and, 146–147  
and dementias, impact of, across cultures,  
94–98

- and related dementias, cholinesterase inhibitors in treatment of, **59-68**
  - anti-inflammatory therapy in, 143
  - antioxidants and, 148
  - apathy in, 37
  - behavioral changes in, 52
  - benzodiazepine receptor modulators and, 148-149
  - cerebrospinal fluid shunting as therapy for, 144-145
  - cholesterol and, 146-147
  - delusions in, 84
  - depression in, 84-85
  - diagnosis of, impediments to, 35-36
  - drug development in, pathways for, **141-152**
    - recent disappointments in, 142-143
  - estrogen replacement therapy in, 142
  - executive or "frontal lobe" function in, 36-37
  - ginkgo biloba and, 148
  - glutamate and, 143-144
  - glycogen synthase kinase-3 in, 144
  - hallucinations in, 84
  - immunization and, 145-146
  - incidence of, 51
  - language difficulties in, 52
  - low education as risk factor for, 102, 103
  - lowering of homocysteine and, 147-148
  - management of, caregiver burden in, evaluation of, 131
    - respite care and, 136
  - caregiver experience in, case history of, 122-124
  - challenges to medical practice, 122
  - community resources in care plan for, 134-135
  - functional assessment in, 131-134
  - hospice care and, 137
  - interdisciplinary approaches to, **121-139**
  - interdisciplinary team for, 124-125
    - nurses on, 126
    - physician on, 125-126
  - long-term care placement in, 136-137
  - memory decline in, 51
  - mild, clinical features of, 35
  - novel treatments against, 317-322
  - passivity and withdrawal in, 37
  - pathologic hallmarks of, 142
  - pathology of, autopsy confirmation of, 97
    - imaging evidence of, 97-98
  - physical aggression in, 84
  - problems of daily function in, screening for, 132-134
  - secretase modulators in, 145
  - self-awareness of, 36
  - self-care deficits in, assessment of, 132
    - $\beta$ -sheet breakers and, 145
    - therapeutic targets in, 143-149
    - versus frontal variant frontotemporal dementia, 37-38
- Alzheimer's Disease Education and Referral Center (ADEAR), 22
- Ambulatory outpatient care, 772
- American Academy of Neurology, mild cognitive impairment and, 21-22
- Amyloid beta protein, Alzheimer's disease and, 317-322
- Anal canal, anatomy and physiology of, changes with aging, 571-573
- Anal sphincter, changes with aging, 571-572
- Anatomic abnormalities, dementia and, 34
- Androgen supplementation, 278
- Antiaging medicine, **157-176**
  - and ethical issues for non-antiaging medicine providers caring for patient, 368-369
  - and methods, for memory, **317-328**
  - as term, 364
  - ethical and legal issues in, **361-382**
  - ethical issues associated with, 362
  - ethics of, and efficacy of therapies, 365-367
  - four features of, 364-365
  - historical background of, 157-159
  - informed consent for, 371-373
  - legal issues associated with, 369-370
  - malpractice issues and, 370, 373
  - patient referral to, 373-374
  - properties of, 364-365
  - regulation of practice of, 369, 374
  - scope of practice and, 374-375
  - standard of care in, lack of, 370-371
  - therapies in, regulation of, 375-377
  - value of, 362-364
- Antiaging products, advertising of, Federal Trade Commission and, 378-379
- Antibodies, to amyloid beta protein, 318-320
- Anticonvulsants, in dementia, agitation and difficult behavior, 77-78
- Antidepressants, 630
  - in dementia, agitation and difficult behavior, 74-75
- Anti-inflammatory therapy, Alzheimer's disease and, 143
- Antipsychotics, in dementia, agitation and difficult behavior, 78

- Antioxidant defense systems, endogenous, 335-339
- Antioxidant vitamins, 262-263
- Antioxidants, Alzheimer's disease and, 148
  - central nervous system and, 330
  - in Alzheimer's disease, 321-322
- Antipsychotics, in dementia, 89
  - agitation and difficult behavior, 76-77
- Antisense, against amyloid beta protein, 320-321
- Anxiety, herbal therapies for, 246
  - whole-patient assessment and, 606
- Apathy, definition of, 50
- Aphasia, progressive nonfluent, 54
- Apitherapy, 168
- Apraxis, 48-49
- Aromatherapy, 161-162
- Atherosclerosis, herbal therapies in, 249-250
- Attention, 48
- Augmentation procedures, in urge incontinence, 532

## B

- Behavior, difficult, and agitation, in dementia, management of, 69-82
- Behavioral changes, in Alzheimer's disease, 52
  - in dementias, 49-50, 84-89
  - management of, 89-90
- Benton Visual Retention Test, 98
- Benzodiazepine receptor modulators, Alzheimer's disease and, 148-149
- Benzodiazepines, 632
- Beta-sitosterols, 242, 243
- Biofeedback, in fecal incontinence, 578-579
  - in urinary incontinence, 504
- Bisphosphonates, 629
- Black cohosh, 243-244
- Bladder, anatomy of, in humans, 412-413
  - function of, 413-414
    - neurologic and neurohumoral control of, 415-417
  - morphology of, 418
  - overactive, afferent innervation and, 415
- Bladder retraining, 498-499

- Blessed test, 5
- Body composition, optimizing of, exercise prescription for, 203-204
- Body fat, total, exercise and, 204
- Bone pain, metastatic, agents for, 629
- Bowel obstruction, malignant management of, 634
- Brain aging, free radicals and, 329-359
  - lipids and proteins in, 339-348
- Breast cancer, 294
- Bristol Female Lower Urinary Tract Symptoms Questionnaire, 554

## C

- Caffeine, as urinary tract irritant, 457
- Calciferol, 262-263, 282-284
- Calcium channel antagonists, in urge incontinence, 431
- Cancer, age as risk factor for, 294-297
  - possible prevention of, in elderly, 293-316
    - prevention of, barriers to, 311
    - levels of, 298
    - primary, 298, 299-305
    - secondary, 298-299, 305-310
    - strategies for, 297-299
    - tertiary, 299
  - screening for. See *Screening for cancer*.
- Carcinogenesis, 295
- Carcinogens, susceptibility of older tissue to, 295-296
- Cardiac dysfunction, at end of life, 652
- Caregivers, categories of, in home health care, 799-800
  - family, and palliative care, 671-688
    - hierarchy of, and persons filling role of, 672-673
  - health needs of, whole-patient assessment and, 613
- Caregiving. See also *Palliative care*.
- Carotenoids, 262
- Carve-outs, in managed care, 773
- Catheters, urinary. See *Urinary catheter(s)*.
- Cat's claw, 248
- Cells, aging, and carcinogens, 296
- Cellular therapy, 168

- Center for Medicare and Medicaid Services (Health Care Financing Administration), 752
- Cerebrospinal fluid shunting, in Alzheimer's disease, 144-145, 322
- Cerebrovascular accident, incontinence in, 481
- Cernilton, 242, 243
- Chelation therapy, 168
- Chemoprevention, of cancer, 303
- Chinese medicine, traditional, 177, 180
- Chiropractic, and geriatrics, **223-235**  
scope of practice, 227
- Chiropractic care, of aging patients, 228-229
- Chiropractic health services, use of, 223-225
- Chiropractic literature, on aging and geriatric care, 228
- Chiropractic techniques, in geriatric care, 230-231
- Chiropractic training, 225-227  
beyond classroom, 226-227  
in geriatrics and gerontology, 226
- Chiropractors, choosing of, 229-232  
on interdisciplinary teams, 227-228
- Chiropractic, 162
- Chlorpromazine (Thorazine), 632
- Cholesterol, Alzheimer's disease and, 146-147
- Cholinesterase inhibitors, in dementia, agitation and difficult behavior, 74  
in treatment of Alzheimer's disease and related dementias, **59-68**
- Civilian Health and Medical Program of Uniformed Services (CHAMPUS), 773, 776
- Clenbuterol, in stress urinary incontinence, 511
- Clergy, Alzheimer's disease and, 129-130
- Clinical Dementia Rating, 17
- Clinical features, 593-594
- Clinical nurse specialists, 126
- Clock Drawing Test (CDT), 5, 6
- Cognition, 47-49  
effects of depression on, 50  
screening of, in dementia, 4-7
- Cognitive dysfunction, 2
- Cognitive factors, urinary incontinence and, 458-460
- Cognitive function, aging and, 16
- Cognitive impairment, alcohol abuse as cause of, 32  
as dementia prequel, 1  
assessment tools for, 4  
causes of, distinctions between, 8  
geriatric assessment for, 1-2  
infection as cause of, 33  
metabolic disturbances causing, tests for, 31-32  
mild, **15-25**, 50-51  
amnesic, 18  
and Alzheimer's disease risk, 19-20, 21  
clinical diagnosis of, 21  
clinical recommendations in, 21-22  
cognitive decline and, 19-20  
consequences of, 19-20  
definition of, 17-18  
incidence of, 18-19  
mortality, institutionalization, and disability and, 19  
ongoing clinical trials on, 22  
Religious Orders Study of, 20-21  
reversible sources of, 31  
risk factors for, 4  
syphilis as cause of, 33  
thyroid dysfunction as cause of, 32  
vitamin B12 deficiency as cause of, 32-33
- Cognitive reserve, 102-103
- Cognitive testing, ethnic background and, in dementias, 98-99
- Comfort care. See *Hospice care*.
- Comforts of home, 164
- Commercial insurance, 769
- Common cold, herbal therapies in, 249
- Communication, 1  
and transitions, in home care, 805  
in goal planning, 614-615  
in spiritual care, 710-711  
with dying patient, discussion with family, 646-647  
with family, at end of life, 642-643
- Community, patient, family, and social context, 669-670  
support of, in health care, 695-696  
support services in, 802
- Community resources, for home care, 801-802  
whole-patient assessment and, 610-611

- Complementary and alternative medicine, 157
  - among older persons, **179-200**
  - around world, understanding of, 179-180
  - asking about use of, 192
  - establishment of goals for, 193
  - historical background of, 157-158
  - in China, 180-182
  - in Europe, 187-188
  - in India, 186-187
  - in Japan, 182-186
  - in South Africa, 188-190
  - in United States, 190-191
  - insurance coverage for, 160
  - recent history of, 158-159
  - recommendations for practitioners of, 192-193
  - scope of practice and, 374-375
  - specific therapeutics and, 160-167
- Constipation, and fecal impaction, management of, 632-633
- Consumer Health Free Speech Act, 377
- Continence care, educational competencies for, 488
- Corticosteroids, in pain management, 625-626
- Cranberry juice, 247
- Creutzfeld-Jakob disease, dementia in, 41
- Custodial care, financing of, 772
- Cystometography, 479
- Cystometry, interpretation of, 419-420

## D

- Daily living, activities of, basic and instrumental activities of, 7
- Death, bereavement after, 661-665
  - epidemiology of, in United States, 735-736
  - facilitation of life closure and, 647
  - good, goal planning, and inflection points, 596
  - in institution, 647-648
  - moving body after, 660
  - notification of coroner, 659
  - notification of family, 659
  - occurrence of, signs of, 645, 657-661
  - things to do upon, 646
  - occurring in nursing homes, 718, 719
  - ongoing support for family following, 647
  - preparation of body for viewing after, 659
  - pronouncing and certifying of, 658
  - religious rituals after, 709-710
  - religious rituals before, 708-709
  - tests of grieving after, 662-665
- Decosohexenoic acid, 341
- Defecation, physiology of, 572-573
- Dehydroepiandrosterone, 279-281
- Delirium, 631-632
  - dementia or depression, conditions associated with, 8, 9
  - distinguishing of, 7-8
  - dementia versus, 30-31
  - terminal, at end of life, 656-657
  - whole-patient assessment and, 606-607
- Delusions, in Alzheimer's disease, 84
- Dementia(s), acculturation and, 100-101
  - agitation and difficult behavior in, assessment of, 69-71
  - management of, **69-82**
    - anticonvulsants in, 77-78
    - antidepressants in, 74-75
    - antipsychotics and other agents in, 78
    - antipsychotics in, 76-77
    - cholinesterase inhibitors in, 74
    - nonpharmacologic principles of, 71-73
    - pharmacotherapies in, 73-78
  - anatomic abnormalities and, 34
  - and Alzheimer's disease, cholinesterase inhibitors in treatment of, **59-68**
  - impact of, across cultures, 94-98
  - and neuropsychologic profiles, 50-54
  - behavioral changes in, 49-50
  - and psychiatric disturbances in, 84
  - environmental causes of, 86-87
  - evaluation of, 85-86
  - medical causes of, 87-88
  - psychiatric causes of, 88-89
  - management of, 89-90
  - clinical assessment for, 2-11
  - clinical criteria for diagnosis of, 28
  - cognition screening in, 4-7
  - cognitive impairment as prequel to, 1
  - construct of, 27-29
  - cortical versus subcortical, classification of, 28-29
  - definition of, 45
  - delirium or depression, conditions associated with, 8, 9
  - distinguishing of, 7-8
  - detection of, across cultures, instrumentation issues in, 98-105
  - diagnosis of, language and, 105-106
  - provider-patient relationship and, 107-108

- socioeconomic status and, 106
  - transportation and neighborhood influencing, 107
  - diagnostic and management considerations in, 105-109
  - differential diagnosis of, 27-43
  - neuropsychologic features in, 45-58
  - due to cerebrovascular disease, 39-40
  - education and, 94
  - and literacy, 101-104
  - end-of-life issues and, 109
  - ethnic differences and cognitive testing in, 98-99
  - evaluation of, flow chart of, 29, 30
  - family support in, 108
  - frontal variant frontotemporal, versus Alzheimer's disease, 37-38
  - frontotemporal, 53-54
  - diagnosis of, 37
  - geriatric assessment for, 2
  - history taking in, 3
  - HIV as cause of, 33-34
  - in Creutzfeld-Jakob disease, 41
  - initial recognition of, 2-3
  - laboratory investigation in, 11-12
  - linguistic issues and, 104-105
  - long-term care in, 108-109
  - management of, in long-term care settings, 83-92
  - medications and, 10-11
  - neuropathologic criteria for, 29
  - normal pressure hydrocephalus as form of, 34-35
  - Parkinson's, 54
  - patient safety and, 8-10
  - physical examination in, 8
  - prevalence of, in nursing homes, 83-84
  - progressive, characterizing of, 35
  - etiologies of, 94
  - racial socialization and, 104
  - recognition and evaluation of, in office settings, 1-14
  - recognition and management of, cultural influences on, 93-119
  - referrals in, 12
  - reversible sources of, identification of, 29-35
  - reversible vascular disturbances and, 34
  - screening for, 1
  - screening tests, 16
  - similarities in presentation of, 45
  - symptoms of, 83
  - treatment options in, 12
  - vascular, 39-40, 53
  - acetylcholinesterase inhibitors in, 63-64
  - versus delirium, 30-31
  - versus depression, 31
  - with Lewy bodies, 38-39, 54
  - acetylcholinesterase inhibitors in, 64-65
- Denervation techniques, in urge incontinence, 531-532
- Depression, dementia or delirium, conditions associated with, 8, 9
- distinguishing of, 7-8
  - dementia versus, 31
  - effects on cognition, 50
  - herbal therapies for, 245-246
  - in Alzheimer's disease, 84-85
  - management of, 629-631
  - signs of, 50
  - urinary incontinence and, 459
  - whole-patient assessment and, 605-606
- Dermatological conditions, herbal therapies for, 251
- Detrusor, composition and function of, 417
- Detrusor myomectomy, in urge incontinence, 532
- Detrusor overactivity, 509-511
- pharmacological therapy of, 518
  - side effects of, 516-517
  - trials of urinary incontinence agents for, 512-515
- Diagnosis Related Group, 768
- Diet, cancer of gastrointestinal and reproductive system and, 300
- Dietary Supplement Health and Education Act (DSHEA), 237-238
- dietary supplements and, 376
  - disease claims and, 376
- Dietary supplements, and vitamins, controlled trials of, in specific diseases, 268-271
- epidemiologic associations with specific diseases, 266-267
  - Federal Trade Commission and, 379
  - Food and Drug Administration and, 237-238, 375-376
  - patient education concerning, 375, 377
- Dietician, Alzheimer's disease and, 129
- Disability, prevention and treatment of, exercise and, 208-211
- sedentariness and, 210
- Disease(s), and vitamins, epidemiological associations of, 272
- chronic, exercise in treatment of, 208
  - prevention of, exercise and, 206-207
  - detectable preclinical phase of, 307
- Donepezil, in Alzheimer's disease, 60, 64-65

- Dong quai, 244
- Drugs, and dementia, 10-11  
 derived from plants, 242  
 development of, in Alzheimer's disease,  
 pathways for, **141-152**  
 for urinary incontinence, negative  
 consequences of, 473  
 used during last hours of life, 648
- Duke Established Populations for  
 Epidemiological Studies of the  
 Elderly (EPESE) project, 95
- Duloxetine, in stress urinary incontinence, 518
- Dying, in hospital, 737-738  
 meaningful, search for, 608  
 process of, changes during, **644-645**  
 management of, 648-657
- Dyspnea, management of, 634-635

## E

- Echinacea, 249
- Education, dementias and, 94, 101-104  
 low, as risk factor for Alzheimer's  
 disease, 102, 103
- Elderly. *See Older adults.*
- Electrical stimulation, in urinary  
 incontinence, 505
- Electromagnetic field therapy, for pelvic floor  
 rehabilitation, 505-506
- Electromyography, 479-480
- Electron paramagnetic resonance spin  
 labeling, 344
- End of life, advance preparation for, 642-648  
 family transitions at, 641-642  
 hospice care at, **753-765**  
 losses for patient and family at, 641  
 medical ethics at, 706-708
- End-of-life care, quality of, in nursing homes,  
 718-721
- End-of-life issues, and dementias, 109
- Energy therapeutics, 165
- English-language tests, dementia detection  
 and, 104-105
- Estrogen receptor modulators, selective, for  
 chemoprevention, 304
- Estrogen replacement therapy, 276-277  
 Alzheimer's disease and, 142
- Ethical issues, and legal issues, in antiaging  
 medicine, **361-382**

- Ethnic background, and cognitive testing,  
 in dementias, 98-99
- Executive function(ing), 49  
 Alzheimer's disease and, 36-37
- Exercise(s), and aging, **201-221**  
 benefits of, 201  
 in prevention and treatment of disability,  
 208-211  
 Kelgel, 432, 499-503  
 risks and benefits of, assessment of,  
 211-212  
 role of, in treatment of chronic  
 disease, 208
- Exercise capacity, maintenance of, 202-203
- Eyes, at end of life, 650-651

## F

- Family, assessment of, in whole-patient  
 assessment, 610-611  
 patient, community, and social context,  
 669-670
- Family care team, development of, 643-645
- Family caregivers, and palliative care,  
**671-688**  
 hierarchy of, and persons filling role of,  
 672-673
- Fecal incontinence, causes of, 573-574  
 diagnostic tests in, 575-577  
 evaluation of, 574-577  
 geriatric, **569-585**  
 history taking in, 574-575  
 importance of, 571  
 physical examination in, 575  
 prevalence of, 569-571  
 risk factors for, 573  
 treatment of, 577-580
- Federal Trade Commission, and advertising of  
 antiaging medicines, 378-379
- Fee-for-service managed care, 773
- Fentanyl (Duragesic), transdermal, 628
- Feverfew, 252
- Financial needs, inquiry into, in whole-patient  
 assessment, 612
- Financing, of US health care, 767-776
- Fluid intake, and dehydration, at end of life,  
 651-652
- Fluoxetine, 246
- Food, Drug and Cosmetic Act (FD&C Act),  
 375, 376-377

- Food and Drug Administration (FDA), dietary supplements and, 237-238, 375-376
- Modernization Act of 1997 (FDAMA), 376
- Food intake, and wasting, at end of life, 650
- Foods, functional, 167
- Forgetfulness, benign senescent, 17
- Frail elderly, with urinary incontinence, **453-466**
  - history questions for, 490
- Free radicals, 331
  - and brain aging, **329-359**
  - formation of, 330-335
- Full capitation, 772-773

## G

---

- Galantamine, in Alzheimer's disease, 62-63, 65
- Gamma-aminobutyric acid, 282, 322
- Gamma-linolenic acid, 248
- Gastrointestinal symptoms, management of, 632-634
- Geriatric Depression Scale (GDS), 5, 6
- Geriatrics, chiropractic and, **223-235**
- Ghrelin, 323-324
- Ginger, 247-248
- Ginkgo biloba*, 245, 246-247
- Ginkgo biloba, Alzheimer's disease and, 148
- Ginseng, 244, 249
- Global budgets, in managed care, 773
- Glucagon-like peptide, 323
- Glutamate, Alzheimer's disease and, 144-145
- Glutathione, 338-339
- Glycogen synthase kinase-3, in Alzheimer's disease, 144-145
- Goal planning, good death, and inflection points, 596
- Gracioplasty, in fecal incontinence, 579
- Growth hormone releasing replacement, 279

## H

---

- Hallucinations, in Alzheimer's disease, 84
- Haloperidol (Haldol), 631

- Healing, perspectives of religions on, 700-702
- Health, role of spirituality and religion in, 691-694
- Health care, in United States, financing of, 767-776
- Health care systems, Federal government funding of, 770
- Heat-shock proteins, 336-338
- Herb-drug interactions, 241
- Herbal preparations, 168
- Herbal therapies, **237-257**
  - documentation of use of, 240-241
  - education of patients concerning, 240-241
  - prevalence of, 238-239
  - reasons for use of, 239-240
- Herbs, 162-163
  - commonly used, 241-252
- High colonics, 168-169
- HIV, as cause of dementia, 33-34
- Home care, advance directives and, 802-803
  - care plan oversight, document for, 805
  - certification activities, document for, 806
  - communication and transitions in, 803-804
  - community resources for, 801-802
  - definition of, 796
  - for frail elderly, **795-807**
    - case study of, 795-796, 804
  - history of, 796-797
  - home visits by physicians in, 800-801
  - managed care and, 773-774
  - medical equipment for, 799
  - needs in, whole-patient assessment and, 613
  - payment for, 797-798, 801
  - qualifying for, needs and, 798-799
- Home care plans, physician supervision of, 798-799
- Home health agency, referral to, reasons for initiating, 798
- Home health care, categories of caregivers in, 799-800
- Homeopathy, 163-164
- Homocysteine, lowering of, Alzheimer's disease and, 147-148
- Hormone replacement therapy, 276-277
- Hormones, as fountains of youth, 167, **275-292**



- Horse chestnut seed, 251-252
- Hospice, PACE and, **783-794**  
     future considerations for, 791-794  
     palliative care, and PACE, compared,  
     786-787
- Hospice care, 774-776  
     and palliative care, in future, 761-762  
     in nursing homes, **717-734**  
     at end of life, **753-765**  
     interdisciplinary care in, 753-756  
     delivery of, 715  
     history of, 751-753  
     in long-term care facilities, 760-761  
     in management of Alzheimer's  
     disease, 137  
     in nursing homes, 724-727  
     interprofessional/interorganizational  
     collaboration in, 728-729  
     palliative care outcomes in, barriers to  
     improvement, 727-729  
     referral to, actions following, 758-759  
     short stays in, 727
- Hospital(s), academic, Medicare and, 770-771  
     acute care in, 768  
     cost avoidance by, 780  
     dying in, 737-738  
     palliative care in. See *Palliative care,*  
     *in hospitals.*  
     urban versus rural, 771
- Human chorionic gonadotropin, 284
- Hupochlorous acid, 332-333
- Hydrocephalus, normal pressure, as form of  
     dementia, 34-35
- Hydrogen peroxide, 332
- 4-Hydroxyl-2-nonenal, 338, 340
- Hydroxyl radical, 333
- Hypericim, 245-246
- Hypnosis, 161

---

**I**

- Imagery, 161
- Immunization, Alzheimer's disease and,  
     145-146
- Incontinence. See also *Fecal incontinence;*  
     *Urinary incontinence.*  
     aging and, 410-411  
     assessment of, 418-419  
     caring for older adult with, advanced  
     practice nursing concepts and,  
     **487-495**  
     categories of, 409-410

- causes of, 412  
     factors predisposing to, 411  
     obesity and smoking and, 411  
     physiology of, **409-425**  
     rhabdosphincter and, 412  
     testing for, 419

- Incontinence Quality of Life, 554
- Incontinent Stress Index, 553
- Incontinent Stress Index Patient  
     Questionnaire, 553
- Infection, and cancer risk, 302  
     as cause of cognitive impairment, 33
- Inflection points, and significant changes, 597  
     good death, and goal planning, 596
- Informed consent, complementary and  
     alternative treatments and, 372  
     description of risks and benefits of  
     treatment and, 372  
     for antiaging medicine, 371-373  
     patient assumption of risks in, 373  
     steps in, 372
- Insurance, commercial, 769
- Interdisciplinary approaches, to management  
     of Alzheimer's disease, **121-139**
- Interdisciplinary team approach, to palliative  
     care, 598
- Iridology, 168
- Irritable bowel syndrome, herbal therapies in,  
     250-251
- Isoprostanes, 341

---

**K**

- Kava, 246
- Kelgel exercises, 432, 499-503
- King's Health Questionnaire, 554

---

**L**

- Language, 49  
     dementias and, 104-105  
     problems of, in Alzheimer's disease, 52
- Lanham Act, 378
- Lawyer, Alzheimer's disease and, 130-131
- Legal issues, and ethical issues, in antiaging  
     medicine, **361-382**
- Levator ani muscles, changes with aging, 572
- Lewy bodies, dementias with, 38-39, 54

- Life-of-life care, practical needs in, 612-613
  - spiritual assessment in, 608-609
- Light therapy, 165
- Lipids, and proteins, modification of, in brain aging, 339-348
  - peroxidation of, 339-343
- Literacy, dementias and, 101-104
- Living, last hours of, 641-667
- Long-term care, in management
  - Alzheimer's disease, 137
  - urinary incontinence and quality improvement in, 537-549
- Long-term care facilities, hospice care in, 760-761
- Long-term care plans, 772
- Longevity, increasing of, effects of exercise on, 206-207
- Lorazepam (Ativan), 632
- Lower urinary tract symptomatology (LUTS), 430-431

## M

- Macular degeneration, herbal therapies for, 246
- Magnet therapy, 166-167
- Malondialdehyde, 340
- Managed care, 769-770
  - capitation and, 769
  - carve-outs in, 773
  - discount fee-for-service and, 769
  - fee-for-service, 773
  - global budgets in, 773
  - home care and, 773-774
  - negotiated per diem rate and, 769
- Massage, 162
- Medicaid, 768-769
  - home health care and, 797-798
- Medical equipment, coverage by Medicare, 799
- Medical ethics, at end of life, 706-708
- Medical licensure, and scope of practice, 374-375
- Medicare, 768
  - academic hospitals and, 770-771
  - fees for home/domiciliary visits, 800-801
  - home health care and, 797-798, 799
  - payment for subacute inpatient care, 771

- Medicare Hospice Benefit, 752, 756-758, 786-787
  - in nursing homes, 724
  - reimbursement for physician services in, 778-780
- Medications. *See Drugs.*
- Medicine, advances in, in last 100 years, 736
- Memory, antiaging methods and medicines for, 317-328
  - declarative, 47-48
  - decline in, in Alzheimer's disease, 51
  - difficulty with, 45
  - impairment of, herbal therapies for, 245-246
  - procedural, 47, 48
  - storage and retrieval of, 48
  - systems of, 47-48
- Menopausal symptoms, herbal therapies for, 243-244
- Merperidine (Demerol), 626
- Metabolic disturbances, causing cognitive impairment, tests for, 31-32
- Methylphenidate, 631
- Midodrine, in stress urinary incontinence, 511
- Migraine, herbal therapies for, 252
- Mind-body connection, 160
- Mini-Mental State Exam (MMSE), 4-5, 6, 94, 99
- Mirtazapine (Remeron), 630
- Mitochondria, as source of oxidants, 330-331, 338
- Modafinil, 631
- Mood stabilizers, in dementia, 89
- Muscle mass, exercise and, 204
- Music therapy, 164

## N

- National Institutes of Health, 22
- Needs at the End-of-Life Screening Tool (NEST), 595, 599, 600-601
- Neosphincter operations, in fecal incontinence, 579
- Neurocognition, measurement of, 46
- Neurologic dysfunction, at end of life, 653
- Neuropathic pain agents, 628

- Neuropsychiatric symptoms, management of, 629-632
- Neuropsychologic assessment, 46-47
- Neuropsychologic profiles, dementia syndromes and, 50-54
- Neuropsychology, clinical, 46
- Nitric oxide, 334
- Nitrogen dioxide, 335
- Nocturia, 483-484
- Nonsteroidal anti-inflammatory drugs, as chemopreventive agents, 305
- Nonsteroidal anti-inflammatory drugs (NSAIDs), in pain management, 624-625
- Nurse(s), licensed practical, qualifications of, 126
- Nurse practitioners, 126
- Nursing care technicians, 127
- Nursing home, urinary incontinence in, evaluation and management of, 437-452
- Nursing home(s), as site of death for older adults, 718
- deaths occurring in, 718, 719
- end-of-life care in, high-quality challenges to providing, 721-724
- quality of, 718-721
- hospice care in, 724-727
- barriers to, 726
- benefits of, 726-727
- inadequate physician presence in, 723
- palliative care and hospice care in, 717-734
- palliative care in, 723-724, 729-730
- reimbursement of, and quality of care, 721-722
- residents of, recognition of status of, 723
- staff of, orientation, knowledge, and skills of, 722-723
- staff turnover in, 721
- staffing shortages in, 721
- Nutrition and Labeling Education Act of 1990 (NLEA), 376
- Nutritionist, Alzheimer's disease and, 128-129
- O**
- 
- Occupational therapist, Alzheimer's disease and, 128
- Oil of evening primrose, 244
- Olanzapine (Zyprexa), 632
- Older adult(s), frail, home care for, 795-807
- with urinary incontinence, 453-466
- history questions for, 490
- health promotion in, remedial risk factors and, 489
- symptom management in, 621-640
- terminal illness in, urinary incontinence and, 467-475
- recommendations for managing, 474
- with incontinence, caring for, advanced practice nursing concepts and, 487-495
- Oncogenes, 296-297
- Opioids, in pain management, 626-628
- parenterally administered, 627-628
- sustained-release, 627
- Oral care, nasal and conjunctival care, at end of life, 652
- Orexins/hypocretins, 324
- Organ donation, view of religions on, 708
- Osteoarthritis, herbal therapies for, 247-248
- Osteoporosis, prevention and treatment of, 203-204
- Overactive Bladder Questionnaire, 553
- Overflow incontinence, with outlet obstruction, pharmacologic therapy for, 518-519
- Overflow urinary incontinence, neuropathic, 430
- obstructive, 430-431
- treatment of, 532-533
- Oxybutinin, in urge incontinence, 431
- P**
- 
- PACE, and hospice, 783-794
- future considerations for, 791-794
- as alternative to hospice, 789-791
- case illustrating, 788-789
- history of, 784-785
- palliative care, and hospice, compared, 786-787
- populations served by, 785-786
- Pain, total, 596
- Pain management, initial considerations in, 621-623
- nonopioids in, 624-626
- nonpharmacologic management in, 623
- pharmacologic management in, 623
- World Health Organization guidelines for, 624

- Palliative care, and hospice care, in future, 761-762  
as expansion of mission of hospice, 785  
caregiver bereavement and, 682-683  
clinical features and, 1-2  
costs of, 673  
delivery of, 715  
family caregivers and, 671-688  
financing of, 767-781  
healing in, spirituality and religion and, 689-714  
hospice care and, in nursing homes, 717-734  
in hospitals, 735-751  
collaboration with hospices, 747-748  
fiscal impact of, 740-741  
optimal use of, barriers to, 741-742  
prevalence and impact of, 739-740  
in nursing homes, 723-724, 729-730  
interdisciplinary team approach to, 598  
interventions for caregivers and, 679-682  
needs of caregivers and, 675-677  
outcomes of, 677-679  
PACE, and hospice, compared, 786-787  
resources of caregivers and, 677  
skilled, definition of, 755  
spirituality and religion and, 690-691  
stress-process model of, 673-675  
stressors of, 675-677  
whole-patient assessment in.  
See *Whole-patient assessment*.
- Palliative care program, successful, development of, 742-743  
team members of, 743  
tools of, 745-747
- Palliative care team, hospital-based, 738-739  
structure and function of, 744-745
- Parkinson's dementia, 54
- Parkinson's disease, acetylcholinesterase inhibitors in, 65  
incontinence in, 480-481
- Passivity and withdrawal, in Alzheimer's disease, 37
- Patient, family, community, and social context, 669-670
- Pelvic floor rehabilitation, 499-506  
electromagnetic field therapy for, 505-506
- Pelvic floor therapy, advanced, 504-506
- Pelvic surgery, in male, incontinence in, 482
- Peppermint oil, 250-251
- Peptides, breaker, in Alzheimer's disease, 321
- Peritoneometry, 504-505
- Peroxyntirite, 334-335
- Pet therapy, 164-165
- Pharmacological therapy, for detrusor overactivity, 518  
side effects of, 516-517
- Phenylpropanolamine, in stress urinary incontinence, 511
- Physical activity. See also *Exercise*.  
levels of, as influence on disease, 206  
patterns of, factors influencing, 206
- Physical aggression, in Alzheimer's disease, 84
- Physical therapist, Alzheimer's disease and, 127-128
- Physician(s), home visits by, in home health care, 800-801  
in nursing homes, 723  
primary, in end-of-life hospice care, 759-760  
reimbursement for home care of elderly, 795, 805, 806
- Physician services, provision of, 776-778  
coding based on time for, 777  
concurrent service and, 778  
diagnosis codes for, 778  
documentation for, 777-778  
procedure/service codes for, 776-777  
reimbursement for, in Medicare Hospice Benefit, 778-780
- Pituitary adenylate cyclase activating polypeptide, 323
- Polyunsaturated fatty acids, 339, 341-342, 343
- Praxis, 48-49
- Pregnenolone, 281-282
- Pressure voiding study, 479
- Program for All-inclusive Care of the Elderly.  
See *PACE*.
- Propoxyphene (Darvon), 626
- Prostate cancer, 294
- Prostatic hyperplasia, benign, 483  
herbal therapies for, 242-243
- Proteins, and lipids, in brain aging, 339-348  
carbonyl levels of, 344, 345  
heat-shock, 336-338  
3-nitrotyrosine levels of, 344, 346  
oxidation of, 343-347

Proteomics, 347-348  
Psychiatric disturbances, in dementias, 84-89  
Psychologic well-being, promotion of, exercise for, 205-206  
Psychosocial factors, in urinary incontinence in elderly, 551-562  
Psychostimulants, 630-631  
Ptah-hotop, 15  
Pulmonary secretions, management of, 635-636  
Pygeum, 242-243

## Q

Quality of life, urinary incontinence and, tools for assessment of, 552-554  
Quality-of-life questionnaires, urinary incontinence and, 552  
Quality-of-life studies, urinary incontinence and, 564

## R

Racial socialization, and dementia, 104  
Raloxifen, as chemopreventive agent, 304-305  
Reactive nitrogen species, 330, 333, 334  
Reactive oxygen species, 330, 331  
Rectum, anatomy and physiology of, changes with aging, 571-573  
Red clover, 244  
Reflex urinary incontinence, 430  
Reflexology, 166  
Religion(s), emphasis on whole person, 694-695  
    perspectives on healing, 700-702  
    perspectives on suffering, 697-698  
    spirituality and. See *Spirituality and religion*.  
    view on organ donation, 708  
Religious Orders Study, of mild cognitive impairment, 20-21  
Religious rituals, after death, 709-710  
    before death, 708-709  
Renal failure, at end of life, 652  
Respiratory dysfunction, at end of life, 654-655

Respiratory symptoms, management of, 634-635  
Retinoids, as chemopreventive drug, 303-304  
Rhabdosphincter, and incontinence, 412  
Rheumatoid arthritis, herbal therapies for, 248  
Risperidone (Risperdal), 632  
Rivastigmine, in Alzheimer's disease, 60, 62, 65

## S

Sacral nerve stimulation, in fecal incontinence, 580  
Sacral root neuromodulation, in urge incontinence, 532  
Saw palmetto, 242  
Scope of practice, antiaging medicine and, 374-375  
Screening for cancer, 305-310  
    detectable preclinical phase and, 307-308  
    glidepaths and, 310  
    in at risk persons, 308  
    lead-time bias and, 309-310  
    measurement of success of, 309  
    risks and adverse effects of, 310  
    statistical components of screening test for, 309  
Scurvy, 79, 80  
Secretase modulators, in Alzheimer's disease, 145  
Secretin, 323  
Sedentariness, disability and, 210  
Seizures, at end of life, 657  
Selective estrogen receptor modulators, for chemoprevention, 304  
Selective serotonin reuptake inhibitors, 630  
Service delivery, 715-716  
Sexual dysfunction, herbal therapies in, 249  
 $\beta$ -Sheet breakers, in Alzheimer's disease, 145  
Skin cancer, sunlight exposure and, 302  
Skin care, at end of life, 649-650  
Sleep aid, herbal therapies as, 248-249  
Sleeping aids, in dementia, 89  
Smoking cessation, for cancer prevention, 299-300

Snoezelen, 165

Social domain, whole-patient assessment and, 609-612

Social workers, Alzheimer's disease and, 127

Soy products, 244

Sphincter control, loss of, at end of life, 656

Sphincter repair, in fecal incontinence, 579

Spiritual assessment, in end-of-life care, 608-609

Spiritual care, as interdisciplinary, 711  
communication in, 710-711

Spiritual domain, whole-patient assessment and, 608-609

Spirituality and prayer, 164

Spirituality and religion, and healing in  
palliative care, **689-714**  
being remembered and, 705  
coping with suffering and, 702-706  
hope and, 703  
in palliative care, 690-691  
life after death and, 705-706  
role in health, 691-694

St John's wort, 245

Stress urinary incontinence, 403, 432-433, 511-518  
bladder neck bulking agents in, 530-531  
in men, artificial urinary sphincter in, 529-530  
in women, 482-483  
artificial urinary sphincter in, 530  
male sling in, 529  
surgical management of, indications and  
technique for, 527  
informed consent for, 527  
retropubic approach for, 527-528  
vaginal approach for, 528-529

Stroke, incontinence in, 481

Suffering, coping with, spirituality and religion and, 702-706  
definition of, 596  
levels of, 696  
perspectives of religions on, 697-698  
physicians and, 696-697

Sunlight exposure, skin cancer and, 302

Superoxide, 332

Supplements, dietary. See *Dietary supplements*.

Swallow, loss of ability, at end of life, 655-656

Syphilis, as cause of cognitive impairment, 33

## T

Tacrine, in Alzheimer's disease, 60

Tai chi, 161

Tamoxifen, as chemopreventive agent, 304

Tea tree oil, 251

Terminal illness, common symptoms in, 469  
concept of, 468-469  
in older person, urinary incontinence and, **467-475**  
recommendations for  
managing, 474  
urinary incontinence in, prevalence  
of, 470

Testosterone replacement, 277-279

Thiobarbituric acid reacting substances, 340-341

Thyroid dysfunction, as cause of cognitive impairment, 32

Tinnitus, herbal therapies for, 246-247

Tobacco smoke, as carcinogen, 299-300

Tolterodine, in urge incontinence, 431

Touch, healing power of, 161-162

Trail Making Tests, 5, 6

Tramadol, in pain management, 625

TURP, in overflow incontinence, 532-533

## U

United States health care, financing of, 767-776

Urge-IIQ, 553

Urge Impact Scale, 553

Urge-UDIQ, 553

Urge urinary incontinence, 403, 431-432  
treatment of, 531-532

Urinary catheter(s), care of, 445, 446-447  
in urinary incontinence, 445-447  
indwelling, negative consequences of, 472-473

Urinary flow rate, measurement of, 480

Urinary incontinence, acute, 428  
advanced practice nursing assessment of, 489-493  
adverse impact on caregiver health, 454  
age and, 564  
and community-dwelling elder, **427-435**

- and quality improvement, in long-term care, **537-549**
- and terminally ill older person, **467-475**
- as multisystem health problem, 493
- as sensitive issue for discussion, 565-566
- behavioral modification in, **497-507**
- behavioral therapies for, 500-502
- biomechanics of, understanding of, 400
- causes of, in nursing home residents, 438-439
- challenges to, in nursing homes, 448-449
- chronic, 428-429
- causes of, 429
- classification of, 525
- cognitive factors and, 458-460
- cost of, in nursing home, 437
- culture and ethnicity and, 565-566
- definition of, 551
- degree of discomfort in, 470
- depression and, 459
- economic impact on society, 401
- epidemiologic overview of, 402-406
- evaluation of, and management of, in nursing home, **437-452**
- in nursing home residents, 439-442
- evidence-based care standards for, **453-466**
- fluid management in, 497-498
- frailty connection with, 455
- functional, 429
- functional factors and, 460-461
- gender and, sexuality, 563-565
- and culture, **563-568**
- global concerns about, 401-402
- government regulations and clinical care guidelines related to, 437
- graphic display of data related to, 540
- high incidence rates of, determination of causes of, 540-541
- historical, global, and epidemiologic perspectives on, **399-407**
- historical evolution of, 399-400
- history questions for evaluation of, 489
- identification of opportunities for improvement in, 538-540
- identification of type of, by advanced practice nurses, 491
- in frail elder, **453-466**
- in terminal illness, prevalence of, 470
- recommendations for managing, 474
- incidence of, in elderly, 551
- laboratory and ancillary work-up in, 526
- laboratory evaluations in, 490-491
- management of, 566
- development of plans for, 543
- evidence-based, 541
- staffing and, 542-543
- strategies for, 433
- management plan for, communication of, 543-544
- evaluation of, 545-547
- feedback and, 545-546
- implementation of, 544-545
- medication for, negative consequences of, 473
- mixed symptomatology in, 440-441
- morbidity associated with, 498
- negative consequences of, 470-472
- overflow, neuropathic, 430
- obstructive, 430-431
- treatment of, 532-533
- with outlet obstruction, pharmacologic therapy for, 518-519
- patient evaluation in, 525-526
- pharmacologic management of, **509-521**
- physical factors associated with, 456-457
- pre-19th century treatment of, 400
- prevalence of, 402, 403, 404, 405, 563
- and impact of, 497, 498
- psychosocial impact of, 554-555
- in elderly, **551-562**
- studies on, 554-557
- qualities of life questionnaires and, 552
- quality-of-life studies and, 564
- reflex, 430
- resident assessment protocol for, 439, 441
- self-treatment of, 565
- setting goals and standards related to, 538
- socioeconomic factors and, 461-462
- staff education and attitudes toward, 541-542
- stress. See *Stress urinary incontinence*.
- surgical management of, **523-535**
- perioperative care for, 524-526
- preoperative assessment for, 524
- surgical procedures in, 526-533
- tools for assessment of, on quality of life, 552-554
- treatment of, behavioral approaches to, 442-444
- catheters in, 445-447
- effect on psychosocial well-being, 557-558
- in nursing home setting, 442
- pharmacologic, 444-445
- preferences for, 447-448
- prompted voiding techniques in, 443
- psychosocial considerations in seeking, 558-559
- urge. See *Urge urinary incontinence*.
- urinalysis in, 526
- Urinary incontinence agents, trials of, for detrusor overactivity, 512-515

Urinary retention, and catheters, 445-447

Urinary tract infection, herbal therapies for, 247

Urodynamic evaluation, bench to bedside, 477-485

Urodynamics, 478-479

Uroflowmetry, 478

Urological Distress Index, 553

## V

Vaginal cones, 503-504

Valerian, 248-249

Vascular disturbances, reversible, dementia and, 34

Vasoactive intestinal peptide, 323

Venous insufficiency, herbal therapies for, 251-252

Videourodynamics, 480

Vitamin(s), and aging, 260-262  
    and dietary supplements, controlled trials of, in specific diseases, 268-271  
    epidemiologic associations with specific diseases, 266-267  
    and disease, epidemiological associations of, 272  
    and health, evidence for, 263-264  
    antioxidant, 262  
    history of, 79-80  
    in health and aging, 259-274

Vitamin A, 262

Vitamin B12 deficiency, as cause of cognitive impairment, 32-33

Vitamin C, 262

Vitamin D, 262-263, 282-284

Vitamin E, 263

## W

Wechsler Adult Intelligence Scale (WAIS), 5, 16

Wechsler Memory Scale (WMS), 5, 94

Whole-patient assessment, 1  
    aim of, 597  
    anxiety and, 606  
    as iterative process, 598  
    assessment of decision-making capacity and, 607

assessment of physical suffering in dying patients, 601-602

assessment of success in psychological domain and, 608

barriers to adequate symptom management and, 602-603

baseline, multiple visits for, 598

community resources and, 605

cultural factors and, 611-612

delirium and, 606-607

depression and, 605-606

evaluation of cause in, 603

evaluation of success in physical domain and, 604

family assessment in, 610-611

financial needs inquiry in, 612

focus on patient function more than pathophysiology, 601

goal planning in, 616

    and inflection points, 595-620

goals of care and advance care planning, 613-616

grief of patient and, 605

health needs of caregivers and, 613

home care needs and, 613

information-sharing preferences and, 612

interdisciplinary team in, 607

Needs at the End-of-Life Screening

    Tool and, 600-601

palliative care model, background of, 596

patient follow-up to assess symptoms, 604

prevention and management of secondary complications in, 603

psychological assessment in, 604-605

review of past medical evaluation and treatment in, 599

social domain and, 609-612

spiritual domain and, 608-609

symptom management in, 603

to assess four dimensions, 597

tools for, 599

Wide Range Achievement Test - version 3 (WRAT-3), 101-102

Wisconsin Card Sorting Task, 98-99

World Health Organization, guidelines for pain management, 624

Wound care, at end of life, 650

## Y

Yoga, 161

York Incontinence Perception Scale, 554



